FDA Cleared and FDA Approved Are Different Evidence Claims

“FDA cleared” and “FDA approved” are not interchangeable. Most devices that reach the US market through a 510(k) submission are cleared after a comparison with a legally marketed predicate, while premarket approval, or PMA, uses a different legal pathway and generally requires an independent showing of safety and effectiveness for a high-risk device.

Key points#

• A 510(k) decision asks whether a new device is substantially equivalent to a legally marketed predicate.
• The new device must have the same intended use and either the same technology or differences that do not raise different safety and effectiveness questions.
• FDA reviews performance evidence appropriate to the device, which may include bench, software, human-factors, animal, and clinical data.
• Clearance does not automatically establish that the device improves patient outcomes, and approval language should not be used for a 510(k) order.
• Readers can inspect the 510(k) summary, predicate, indications for use, performance tests, recalls, and postmarket evidence.

Start with the pathway, not the marketing adjective#

Medical devices are regulated according to classification, risk, and the available pathway. Some low-risk devices are exempt from premarket notification. Many moderate-risk devices use 510(k). Many high-risk devices use PMA. A novel low-to-moderate-risk device with no suitable predicate may use the De Novo pathway to establish a new classification that later devices can cite.

These categories have exceptions, so check the device's actual FDA record rather than infer the pathway from how advanced or familiar the product looks to you.

A 510(k) is called a premarket notification, but it is a substantive submission, not a one-page notice; FDA says the submission must contain enough detail to determine substantial equivalence, and its own content page notes that a typical file can run dozens of pages. The word “clearance” describes the decision standard. It does not mean the agency ignored safety or performance.

The substantial-equivalence test#

The comparison begins with intended use. The proposed device and predicate must have the same intended use. FDA then considers technological characteristics.

If the technology is the same, the path is relatively direct. If it differs, the differences must not raise different questions of safety and effectiveness, and the submitted information must show that the new device is as safe and effective as the predicate for the intended use. Substantial equivalence does not require the devices to be identical.

The review can consider design, materials, energy delivered, performance, software, cybersecurity, biocompatibility, sterility, labeling, human factors, and other features relevant to the product. Device-specific standards and guidance can define additional tests. That is a real review, and its anchor remains comparative: whether the new product is sufficiently equivalent to a lawful device already on the market.

Evidence can be extensive without being a clinical-outcome trial#

Most 510(k)s include some performance data. The appropriate package depends on what could go wrong and what changed from the predicate.

A mechanical implant may need fatigue and wear tests. A sterile product may need validation of sterilization and packaging. Software may need verification, validation, cybersecurity documentation, and testing across relevant inputs. A home-use device may need human-factors evidence showing that intended users can operate it safely. A diagnostic test may need analytical and clinical performance studies.

FDA can request clinical performance data when nonclinical evidence cannot resolve the equivalence question, and the presence of clinical data does not convert the pathway into PMA, just as the absence of a randomized outcomes trial does not mean no performance testing occurred.

This distinction protects against two opposite errors. It is too strong to say that a cleared device was “proved effective” in the same sense as a successful clinical-outcome trial. It is also inaccurate to say that clearance is merely paperwork with no evidence review.

Why the predicate matters#

The predicate defines the comparison. A useful reading therefore asks:

• What device served as the primary predicate?
• Was it recently cleared or a much older product?
• Does it have the same indications for use?
• Which technological features differ?
• What evidence addresses those differences?
• Has the predicate been recalled or linked to a known safety issue?
• Does the new device rely on a chain of earlier predicates?

Predicate chains can be reasonable because technologies evolve through incremental changes. They can also make it hard for a reader to identify the evidence supporting the original design concept; FDA has modernized its program and encourages appropriate predicate selection, while its databases let you examine the chain and the decision summaries. A predicate's age alone does not establish that it is unsuitable; the concern is whether current differences raise questions that the comparison and testing package answer adequately.

What PMA means instead#

PMA is generally used for Class III devices that support or sustain life, prevent major impairment, or present a potentially unreasonable risk, and its standard requires valid scientific evidence providing reasonable assurance of safety and effectiveness for the device's intended use.

That may include clinical investigations, manufacturing information, design controls, labeling, and other evidence. Approval can include conditions and post-approval study requirements. PMA is more demanding, but the word “approved” should still not be inflated into a claim that every possible use has been shown beneficial or that no uncertainty remains.

De Novo authorization occupies another place. It provides a route for a novel low-to-moderate-risk device without a legally marketed predicate, creating a classification and special controls, and marketing copy that collapses 510(k), De Novo, PMA, and emergency-use authorities into one generic FDA badge deprives readers of the evidence context.

How to investigate a specific device#

FDA's public databases are more informative than a product landing page. A structured review can include:

1. Find the 510(k), De Novo, or PMA number.
2. Confirm the exact device name, applicant, product code, and decision date.
3. Read the indications for use, including population, setting, and limitations.
4. Read the 510(k) summary or decision summary for the predicate and tests.
5. Separate bench, analytical, human-factors, and clinical evidence.
6. Check labeling for contraindications, warnings, and required training.
7. Search recalls and safety communications for both the device and product family.
8. Look for postmarket studies and comparative clinical research.

The question “Is it cleared?” is only the first gate. A care decision may also depend on diagnostic accuracy, absolute benefits and harms, usability, operator skill, alternative options, cost, and performance in the population you are treating.

Reading common claims accurately#

“FDA registered” usually refers to establishment registration or device listing, not a premarket finding that a product is safe or effective. “FDA compliant” is too vague without naming the requirement. “FDA certified” often has no defined meaning for the claim being made. For a 510(k) product, the precise language is that FDA cleared the device for specified indications after finding it substantially equivalent to a named or identifiable predicate. If a company tells you “approved,” check whether a PMA or another approval pathway actually exists.